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Abstract
Purpose The epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) is
approved for cancer treatment. We investigated whether
gefitinib treatment can enhance human EGF (hEGF) uptake
in vitro, thereby increasing the potential of hEGF as a
vehicle for EGFR-targeted therapy.
Methods Western blotting was used to detect the effect of
gefitinib on EGFR signaling. Different EGFR-expressing
tumor cells (SCC-1, 22B, A549, and HT-29) were pre-
treated with gefitinib, and then with 125I-hEGF or 125I-
Vectibix (an anti-EGFR monoclonal antibody). Cell-asso-
ciated activity was then measured. A cross-linking assay
detected increased EGFR dimer formation in gefitinib-
treated cells.
Results Total EGFR levels were not changed, but EGFR
phosphorylation was reduced in cells pretreated with gefi-
tinib. Gefitinib mediated formation of EGFR dimers;
binding of 125I-hEGF to cells pretreated with gefitinib
significantly increased. In contrast, binding of 125I-Vectibix
to tumor cells did not increase. Although total EGFR levels
did not increase, binding of hEGF to EGFR ? tumors was
significantly enhanced after gefitinib treatment, because of
increased hEGF binding to gefitinib-induced EGFR dimers.
Conclusion These results suggest that hEGF could
enhance EGFR-targeting when used with gefitinib.
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Introduction
Receptor tyrosine kinases of the epidermal growth factor
receptor (EGFR) family are critical in the etiology and
progression of solid tumors. EGFR is associated with
essential cellular functions, including proliferation,
migration, survival, and differentiation [1, 2]; it is over-
expressed in many tumors, including head and neck, renal,
lung, glioma, breast, colorectal, prostate, ovarian, bladder
and pancreas [3], and prompts more aggressive malignant
phenotypes and poor prognoses. For such reasons, EGFR is
an attractive target for tumor therapies. Gefitinib (ZD1839,
IressaTM) is an anilino-quinazoline derivative that acts as
an EGFR-specific pharmacological inhibitor; it decreases
EGFR kinase activity by binding the adenosine triphos-
phate (ATP) pocket of the catalytic domain [4]. Although
patients with high EGFR expression reportedly have sig-
nificantly worse survival, gefitinib induces substantial
clinical responses in about 10 % of patients with chemo-
therapy-refractory NSCLC [5–8]. Generally, gefitinib-
responsive lung cancers—but not nonresponsive cancers—
harbor mutations within the EGFR kinase domain [9, 10].
These heterozygous mutations include small in-frame
deletions and missense substitutions clustered within the
ATP-binding pocket.
The natural ligand to the EGFR, hEGF, is a peptide with
a molecular weight of about 6 kDa. Reportedly, the EGFR-
specific TKIs AG-1478 and AG-1517 both compete with
ATP in the classical mode of action, and induce formation
of inactive, unphosphorylated EGFR dimers, even in the
absence of ligand hEGF [11, 12]. The same phenomenon
was also observed in cells treated with gefitinib. Gefitinib
induces formation of inactive EGFR/HER2 and EGFR/
HER3 heterodimers in HER2-overexpressing breast cancer
cells [13]. In A431 cells, gefitinib increased the number of
P. He  G. Li (&)
Department of Biochemistry and Molecular Biology,
Peking University Health Science Center, Beijing 100191,
People’s Republic of China
e-mail: ligang55@bjmu.edu.cn
123
Cancer Chemother Pharmacol (2013) 72:341–348
DOI 10.1007/s00280-013-2198-6
EGFR dimers 3.0–3.8 times in the absence of hEGF [14].
In hEGF-stimulated SKOV3 cells, EGFR dimers were also
increased 1.8–2.2 times by gefitinib, but this effect was
cancelled by pertuzumab [14]. As receptor dimers are
thought to have high affinity for their ligand, uptake of
211At-hEGF in U343 cells markedly increased (up to 3.5
times) in cells pretreated with gefitinib [15]. Gefitinib
treatment increased EGFR Bmax by membrane stabilization
of inactive receptor dimers in the absence of hEGF [16].
Taken together, we supposed that gefitinib induces
EGFR dimer formation, thus affecting ligand interactions.
This indicates that combined gefitinib treatment and
radionuclide targeting to EGFR would be a useful thera-
peutic modality, even for patients who express high EGFR
levels and do not respond to treatment with gefitinib alone
or other EGFR-targeted therapeutic methods.
Materials and methods
Cell culture
Four cell lines were used: human head and neck squamous
carcinoma cell line UM-SCC-22B and SCC1, human colon
carcinoma cell line HT29, and human nonsmall cell lung
carcinoma cell line A549. All cells were cultured in
DMEM supplemented with 10 % fetal bovine serum (FBS)
at 37 C in 5 % CO2.
Radiolabeling
Human epidermal growth factor (hEGF, Chemicon Inter-
national, USA) and Vectibix (an anti-EGFR mAb, Amgen,
Inc.) were labeled with 125I (Beijing Atom High Tech,
Beijing, China) using the Iodogen method for all cellular
experiments. The methods were performed as described
previously [17–19].
Cell-binding assay
Different EGFR-expressing tumor cells seeded in 24-well
plates were pretreated with gefitinib at a single dose
(400 nM) for 1 h at 4 C, incubated by addition of 125I-
hEGF or 125I-Vectibix for another 2 h at 4 C. The total
volume of each well was adjusted to 200 ll. Nonspecific
binding at each well was determined by adding the same
dose of 125I-hEGF or 125I-Vectibix in the absence of cells.
After incubation, the reaction medium was removed and
cells were washed with ice-cold PBS. Cells were lysed with
2 M NaOH, and cell-associated radioactivity was measured
using a gamma counter (Wallac 1470-002, Perkin-Elmer,
Finland). Results were analyzed by GraphPad Prism 4.0
(GraphPad Software, San Diego, CA). Data were expressed
as the average of triplicate samples. Cells were adminis-
trated with DMSO as vehicle control.
Cells were pretreated with gefitinib at a continuous
dose of 0.01, 0.05, 0.1, 0.5, 1, 5, or 10 lM for 1 h at
4 C, incubated by addition of 125I-hEGF for another 2 h
at 4 C. Then, the next steps were performed as described
above.
hEGF affinities that were affected by gefitinib were
determined by performing competitive displacement stud-
ies using 125I-hEGF as the radioligand. 125I-hEGF was
prepared by labeling hEGF with Na125I at a high specific
activity (RCP = 100 %) according to the method descri-
bed previously. Briefly, multiscreen DV filter plates were
seeded with *105 cells in the binding buffer and incubated
with gefitinib at a single dose (10 nM) for 1 h at 4 C.
Cells were then washed with ice-cold PBS and incubated
with 125I-hEGF in the presence of increasing concentra-
tions of hEGF (0–10 lg/ml). After removing the unbound
125I-hEGF, hydrophilic PVDF filters were collected and the
radioactivity was determined using a gamma counter
(Packard, Meriden, CT). All the in vitro experiments were
carried out twice with triplicate samples. Nonspecific
binding at each well was determined by adding a high
concentration of cold hEGF (400 ng/ml) that completely
displaced ([95 %) radiolabeled hEGF binding. Cells
treated with DMSO were used as control. Results were
calculated by nonlinear regression using GraphPad Prism
(GraphPad Software, Inc., San Diego, CA), and reported as
an average of these samples plus the standard deviation.
For comparison purposes, we also evaluated Vectibix using
the same method in vitro assay.
Western blotting
Different EGFR-expressing tumor cells were pretreated
with gefitinib at different concentrations in the presence of
hEGF (10 lM). Cells were then collected and lysed in cell
lysis buffer (50 mM Tris–HCl, pH 7.4, 1 % NP-40, 0.25 %
sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM
Na3VO4, 1 mM NaF) containing protease inhibitors. After
the insoluble part of the lysates was cleared by centrifu-
gation, protein concentrations were determined by the BCA
Protein Assay Kit (Pierce). Forty micrograms of proteins
was separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto a
nitrocellulose (NC) membrane. The primary antibodies
used for western blot analysis were against EGFR (SC-05,
Santa Cruz), and pEGFR (#2231, Cell Signaling). GAPDH
was used as loading control. Bands were detected by
enhanced chemiluminescent western blotting detection
system (GE Healthcare). Films were then scanned by
grayscale mode, and the images were opened in ImageJ
(http://rsb.info.nih.gov/ij/).
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Cross-linking assay
Before cross-linking, the cells were serum-starved for 24 h
in 0.1 % FBS DMEM. Cells were then exposed to gefitinib
at concentrations of 0 , 0.01 , 0.05, 0.1, 0.5, 1, 5, or 10 lM
(final concentration) for 1 h at 37 C, followed by incu-
bation with 100 ng/ml hEGF, or without hEGF as positive
control. After being washed three times with ice-cold PBS,
1 mM of the cross-linking reagent BS3 in cold PBS was
added to cells and maintained on ice for 30 min. The
reaction was stopped by 500 mM (final concentration) of
glycine in PBS for 5 min at 4 C. Subsequently, cells were
washed with ice-cold PBS, and then scraped in lysis buffer
as described previously. After centrifugation at 10,000g for
15 min at 4 C, the supernatants were collected and protein
concentrations were determined by the BCA Protein Assay
Kit (Pierce). Proteins were separated by SDS-PAGE on
6 % gel; western blot analysis was done as described
previously. The primary antibodies were against EGFR
(SC-05, Santa Cruz). An ROI was drawn on the first lane;
the same size/shape ROI was also applied to the other
lanes. Each intensity band correlated with the cell-binding
data.
Statistical analysis
Quantitative data were expressed as mean ± SD. Statisti-
cal analysis was done by one-way ANOVA and Student’s
t test. P \ 0.05 was considered statistically significant
(GraphPad Prism 4.0).
Results
Effects of gefitinib on EGFR expression and receptor
phosphorylation
To determine the effects of gefitinib on EGFR expression
and receptor phosphorylation, four tumor cells (SCC-1,
22B, A549, and HT-29) were pretreated with gefitinib at
0.00, 0.05, 0.1, 0.5, or 1 lM in the presence of hEGF
(10 lM), followed by western blot analysis. As shown in
Fig. 1a, these four cell lines showed even levels of EGFR
expression, which was not affected by gefitinib, but the
phosphorylation of EGFR showed dose-dependent
decrease when treated with gefitinib. However, phosphor-
ylation of EGFR in 22B cells did not indicate a dose-
dependent decrease.
Effects of gefitinib on 125I-hEGF binding to cells
Cells were pretreated with gefitinib at a single dose
(400 nM), followed by addition of 125I-hEGF or 125I-
Vectibix. Binding of 125I-hEGF to gefitinib-treated cells
was significantly increased, whereas binding of 125I-Vec-
tibix to tumor cells did not increase (Fig. 1b).
Gefitinib mediated formation of EGFR dimer
complexes
EGFR dimerization is reportedly induced by its specific
ligand; it is also mediated by quinazoline derivatives in the
absence of growth factor [13]. We verified that this phe-
nomenon appeared in different EGFR-expressing tumor
cells (A549, 22B, HT-29, and SCC1) after gefitinib treat-
ment. EGFR dimer formation was detected by western blot
experiments, after membrane protein cross-linking, fol-
lowing administration of gefitinib. EGFR monomers
(molecular mass 170 kDa) were present in both untreated
and drug-treated cells at equal amounts, even at different
doses of gefitinib (Fig. 2). However, clear dimerization of
EGFR (at *360 kDa immunoreactive bands) was also
evident in the four different tumor cells, and in cells
exposed to hEGF (100 ng/ml) treatment; such dimerization
gradually increased with the dose of gefitinib at 0.01, 0.05,
0.1, 0.5, 1, 5, and 10 lM (final concentration). Notably,
SCC1 cells floated when doses of gefitinib exceeded
0.5 lM, so we only obtained results from 0 to 0.5 lM
doses.
hEGF uptake correlated with increased EGFR dimer
formation and change of gefitinib dose
To determine the correlation between hEGF uptake
increase and EGFR dimer formation, we also carried out
cell binding of 125I-hEGF after gefitinib treatment at con-
tinuous doses of 0.01, 0.05, 0.1, 0.5, 1, 5, or 10 lM in cells.
We then conducted quantitative densitometry of EGFR
dimers, compared the results with those of 125I-hEGF cell
binding at continuous gefitinib doses, and analyzed the
correlation between hEGF uptake increase and EGFR
dimer formation. Western blot analysis of EGFR dimers by
ImageJ was used to obtain quantitative data (Fig. 3). Rel-
ative hEGF uptake was calculated to correlate with the
EGFR dimer formation. In all four tumor cell lines, EGFR
dimerization and specific binding of hEGF increased with
increased gefitinib dose. We therefore supposed that
increased hEGF uptake has a better linear correlation of
EGFR dimer formation with the change in gefitinib dose,
(r2 = 0.9127 in A549, r2 = 0.9464 in 22B, r2 = 0.6426 in
HT29, and r2 = 0.6417 in SCC1; P \ 0.0001).
Gefitinib increased number of hEGF receptor sites
The receptor-binding affinity of hEGF treated with gefiti-
nib was determined using competitive displacement
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studies, with Vectibix as control. hEGF and Vectibix
inhibited binding of 125I-hEGF and 125I-Vectibix to cells,
in a concentration-dependent manner (Fig. 4). The results
suggest that the gefitinib did not affect the receptor-binding
affinities of hEGF and Vectibix. However, hEGF receptor
site numbers increased after gefitinib treatment, whereas
those for Vectibix did not change, which indicates that
gefitinib caused a dramatic increase in radioligand specific
binding.
Discussion
Because of the apparent role of EGFR in tumor aggression
and poor prognosis, and its high expression in many types
of cancers, the EGFR pathway has been well investigated
as a possible target in cancer therapies. Increasing clinical
evidence has shown the disparity between the EGFR
expression level and the treatment effect of anti-EGFR
mAb-based immunotherapeutic agents [20–22]. Epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs) such as gefitinib represent another strategy for
EGFR-targeted cancer therapy. However, gefitinib induces
substantial clinical responses in only about 10 % of
patients with chemotherapy-refractory NSCLC [5–8].
Besides EGFR expression levels, other factors, such as
EGFR mutations, tumor microenvironment, tumor vascu-
lature density and permeability, tumor interstitial pressure,
pharmacokinetics, and tumor penetration ability of com-
pounds, could influence anti-EGFR treatments [8, 9, 23,
24].
In our study, western blot was performed with different
EGFR-expressing tumor cells (SCC-1, 22B, A549, and HT-
29) to detect the effects of gefitinib on EGFR expression
Fig. 1 a Effects of gefitinib on EGFR expression and receptor
phosphorylation in A549, 22B, HT29, and SCC1 cancer cells.
b Binding of 125I-hEGF to cancer cells pretreated with 400 nM
gefitinib. The values on the y-axis give the percentage of added
radioactivity. Each data point is an average value from three
wells ± maximum error
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and receptor phosphorylation. Although the total EGFR
levels were unchanged, EGFR phosphorylation was
reduced in SCC1, HT29, and A549 cells pretreated with
gefitinib (Fig. 1a). However, in 22B cells, EGFR phos-
phorylation was not decreased in a significant dose-
dependent manner when treated with gefitinib, which
suggests that the 22B tumor cells are tolerant to gefitinib.
When 125I-hEGF was added to cells pretreated with gefi-
tinib, an unexpected two–threefold increase was observed
(Fig. 1b). Furthermore, the increase was dependent on the
drug concentration (Fig. 3). However, 125I-Vectibix did not
show the same increase (Fig. 1b). Our results indicate that
hEGF uptake was significantly increased after gefitinib
treatment in EGFR ? cells, even in the cells tolerant to
gefitinib.
hEGF can induce transphosphorylation of their recep-
tors, mainly by forming monomeric receptors into active
dimers. However, quinazoline drugs can induce
sequestration of EGFR into inactive dimers [25], and trap
the ligand into those complexes, which can block the
ligand from binding to still-functional receptors. This pat-
tern is consistent with gefitinib directly promoting forma-
tion of inactive EGFR-based homodimers or heterodimers
(EGFR/HER2, EGFR/HER3) in several breast carcinoma
cell lines [13]. Gefitinib is reported to competitively inhibit
ATP binding at the catalytic site of EGFR tyrosine kinase
[26]. Some studies showed that gefitinib can cause com-
plete and long-lasting inhibition of EGFR phosphorylation,
which depends on sequestration of inactive drug–receptor
complexes in breast and ovarian carcinomas [13, 27].
Interaction of anilino-quinazoline-induced receptor dimer-
ization at the ATP-binding site has been reported even in
the absence of ligand binding [11]. Therefore, we
hypothesized that the increased hEGF uptake may be due
to gefitinib-induced formation of inactive dimers, and such
dimers could be responsible for the apparent increase in
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Fig. 2 Chemical cross-linking to evaluate EGFR dimerization after gefitinib and/or EGF treatment in A549, 22B, HT29, and SCC1 cancer cells.
EGFR dimer formation was evaluated by analysis of gray value
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Fig. 3 Correlation of hEGF tumor uptake and formation of EGFR dimer dose dependent on gefitinib in A549, 22B, HT29, and SCC1 cancer
cells
Fig. 4 In vitro inhibition of 125I-hEGF (left) and 125I-Vectibix (right) binding to EGFR on A549, 22B, HT29, and SCC1 cancer cells by hEGF
(left) and Vectibix (right). Points mean (n = 3), bars SD
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EGFR binding sites. We confirmed significantly increased
EGFR dimerization after gefitinib treatment, which grad-
ually increased with gefitinib dose (Fig. 2). An even better
linear correlation between hEGF uptake increase and
EGFR dimer formation was seen as gefitinib dose increased
(Fig. 3). Additionally, the dimers stabilized in the non-
phosphorylated (inactive) state in the presence of hEGF
(data not showed), as previously reported [14]. Thus, sta-
bilization of inactive dimers may represent another way by
which gefitinib impairs EGFR activity. The competitive
cell-binding assay showed that the affinity of EGFR was
not significantly changed after gefitinib treatment, but the
hEGF receptor site numbers (but not those for Vectibix)
were increased after gefitinib treatment (Fig. 4). It may be
hypothesized that either the gefitinib-dependent EGFR
dimerization exposed new binding sites in the inactivated
receptors or that dimerization allows hEGF access to spare
receptors sequestered in membrane compartments that
prevent ligand binding in untreated cells.
Although our previous study [25] independently dem-
onstrates that formation of nonfunctional EGFR dimers can
be induced by gefitinib, the exact molecular mechanism
linking both events is unclear. However, this study is the
first to report the correlation between increased 125I-hEGF
and EGFR dimer formation with changes in gefitinib dose.
In summary, the main goal of this study was to establish a
basis for investigating the mechanism of gefitinib-mediated
increase in hEGF uptake. Although total EGFR levels did not
increase, the binding of hEGF to EGFR ? tumors was sig-
nificantly enhanced after gefitinib treatment, which is likely
due to hEGF binding to increased numbers of gefitinib-
induced EGFR dimers. These results suggest that hEGF
could enhance EGFR-targeting when used with gefitinib.
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